Alsterpaullone, cyclin-dependent kinase (CDK) and GSK-3beta inhibitor (ab141070)
Key features and details
- Potent cyclin-dependent kinase (CDK) and GSK-3β inhibitor
- CAS Number: 237430-03-4
- Purity: > 96%
- Form / State: Solid
- Source: Synthetic
Overview
-
Product name
Alsterpaullone, cyclin-dependent kinase (CDK) and GSK-3beta inhibitor -
Description
Potent cyclin-dependent kinase (CDK) and GSK-3β inhibitor -
Biological description
Potent CDK inhibitor (IC50 values are 3.5 (CDK1/cyclin B), 20 (CDK2/cyclin A) and 40 nM (CDK5/p35)). Also displays potent and selective inhibition of GSK-3β (IC50 values are 40 and 4 nM respectively). Antiproliferative effects seen in vitro. Cell-permeable. -
Purity
> 96% -
CAS Number
237430-03-4 -
Chemical structure
Properties
-
Chemical name
7,12-Dihydro-9-nitroindolo[3,2-d][1]benzazepin-6(5H)-one -
Molecular weight
293.28 -
Molecular formula
C16H11N3O3 -
PubChem identifier
5005498 -
Storage instructions
Store at +4°C. Store under desiccating conditions. The product can be stored for up to 12 months. -
Handling
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
-
SMILES
[O-][N+](=O)c4cc3c(NC1C3CC(=O)Nc2ccccc12)cc4 -
Source
Synthetic
-
Research areas
- Metabolism
- Pathways and Processes
- Metabolic signaling pathways
- Energy transfer pathways
- Integration of energy
- Biochemicals
- Research Area
- Alzheimer's Disease
- Apoptosis & cell cycle
- Cyclin-dependent kinase
- Inhibitors
- Biochemicals
- Research Area
- Alzheimer's Disease
- Signaling
- Apoptosis & cell cycle
- Cyclin-dependent kinase
- Inhibitors
- Biochemicals
- Research Area
- Diabetes
- Signaling
- Apoptosis & cell cycle
- Cyclin-dependent kinase
- Inhibitors
- Biochemicals
- Research Area
- Hypertension
- Signaling
- Apoptosis & cell cycle
- Cyclin-dependent kinase
- Inhibitors
- Biochemicals
- Research Area
- Obesity
- Signaling
- Apoptosis & cell cycle
- Cyclin-dependent kinase
- Inhibitors
- Biochemicals
- Research Area
- Pain & inflammation
- Apoptosis & cell cycle
- Cyclin-dependent kinase
- Inhibitors
Images
-
Chemical Structure - Alsterpaullone, cyclin-dependent kinase (CDK) and GSK-3beta inhibitor (ab141070)2D chemical structure image of ab141070, Alsterpaullone, cyclin-dependent kinase (CDK) and GSK-3beta inhibitor
-
Functional Studies - Alsterpaullone, cyclin-dependent kinase (CDK) and GSK-3beta inhibitor (ab141070)ab32505 staining AKT1 in SK-N-SH cells treated with alsterpaullone (ab141070), by ICC/IF. Decrease of AKT1 expression correlates with increased concentration of alsterpaullone, as described in literature.
The cells were incubated at 37°C for 6h in media containing different concentrations of ab141070 (alsterpaullone) in DMSO, fixed with 4% formaldehyde for 10 minutes at room temperature and blocked with PBS containing 10% goat serum, 0.3 M glycine, 1% BSA and 0.1% tween for 2h at room temperature. Staining of the treated cells with ab32505 (1/200 dilution was performed overnight at 4°C in PBS containing 1% BSA and 0.1% tween. A DyLight 488 anti-rabbit polyclonal antibody (ab96899) at 1/250 dilution was used as the secondary antibody. Nuclei were counterstained with DAPI and are shown in blue.
Protocols
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
Datasheets and documents
-
SDS download
-
Datasheet download
References (0)
ab141070 has not yet been referenced specifically in any publications.